# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study dataOngoing...
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of ...
Leerink Partners analyst Joori Park initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and an...
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...
Larimar Therapeutics (NASDAQ: LRMR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate ...
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...